S. Fukushi

Impact of reinfection with SARS-CoV-2 Omicron variants in previously infected hamsters

This study investigates reinfection with SARS-CoV-2 Omicron variants in previously infected hamsters, finding that immunity prevents pneumonia but allows viral replication in the upper airways with increased mutation diversity.

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

This study evaluates the replicative ability and pathogenicity of SARS-CoV-2 BA.2.75 isolates in Syrian hamsters, finding higher lung replication and focal pneumonia compared to BA.2 and BA.5.

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

The paper compares the efficacy of neutralizing antibodies and antiviral drugs against SARS-CoV-2 Omicron subvariants BA.1 and BA.2, finding differential responses to specific treatments.

Two doses of mRNA vaccine elicit cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant

The paper shows that two doses of mRNA vaccine generate cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant, which are retained and contribute to enhanced antibody responses after a third dose.

Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro

This study identifies Mefloquine as a potent in vitro entry inhibitor of SARS-CoV-2 with higher antiviral activity than Hydroxychloroquine.

The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells

This paper identifies ciclesonide as an inhaled corticosteroid that inhibits SARS-CoV-2 replication by targeting the viral replication-transcription complex in cultured cells.

Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein

This study evaluates SARS-CoV-2 neutralizing antibodies using a pseudotyped virus assay and compares results with immunofluorescence assay findings.

A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome

This paper develops and tests recombinant vaccinia virus vaccines against SFTS, showing they induce protective immunity and are safe in mice.

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

The paper identifies ciclesonide as a corticosteroid that inhibits coronavirus replication by targeting NSP15, with resistance emerging through an amino acid substitution.

Characterization of the untranslated region of lymphocytic choriomeningitis virus S segment

This study investigates the functional roles of untranslated regions (UTRs) in the LCMV S segment, revealing their involvement in viral replication, transcription, and virulence, with implications for vaccine development.

Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: dose-efficacy studies upon oral administration

This study shows that oral favipiravir at 120 or 200 mg/kg/day effectively treats SFTSV infection in IFNAR-/- mice when started within 4 days post-infection, preventing mortality.